Core Viewpoint - China Galaxy Securities emphasizes the dual strategy opportunities in the pig farming industry, predicting a year-on-year decline in pig prices for 2026, with potential rebounds during the year due to policy-driven capacity reduction and industry losses [1] Group 1: Pig Farming Industry - In January 2026, the Consumer Price Index (CPI) increased by 0.2% year-on-year, with food prices declining by 0.7%, and pork prices down by 13.7% year-on-year [1] - The pig price on February 11 was 12.75 yuan/kg, up 2.7% from the end of 2025, but the industry is facing losses, with self-breeding and external piglet farming profits at -159.65 yuan/head and 20.83 yuan/head respectively [3] - The number of breeding sows in China at the end of 2025 was 39.61 million, a decrease of 2.9% year-on-year, indicating potential accelerated capacity reduction in the industry due to ongoing losses [3] Group 2: Agricultural Index Performance - In February, the agricultural index underperformed the CSI 300, with a decline of 0.14%, while the breeding industry saw a relative increase of 1.02% [2] Group 3: Pet Food Industry - In December, China's pet food export value was 906 million yuan, down 2.91% year-on-year, with export volume increasing by 15.49% but average export price dropping by 15.93% [4] - For the year 2025, the total export value of pet food was 10.102 billion yuan, a decrease of 4.1% year-on-year, with export volume at 361,300 tons, an increase of 7.8%, and average export price down by 11% [4]

Group 1 - The core viewpoint of the article highlights that Shenlian Bio reported a revenue of approximately 288 million yuan for the year 2025, representing a year-on-year decrease of 4.99% [1] - The net profit attributable to shareholders of the listed company was a loss of 19.09 million yuan, compared to a loss of 44.74 million yuan in the same period last year [1] - The basic earnings per share for the company was a loss of 0.05 yuan, an improvement from a loss of 0.11 yuan in the previous year [1] Group 2 - The article also mentions a significant shift in AI usage, with China surpassing the United States in AI call volume, leading to a surge in various sectors in the A-share market [1] - A well-known Wall Street analyst commented on China's computing power path, suggesting it disrupts traditional perceptions [1]

Core Viewpoint - The company reported a revenue of approximately 288 million yuan for the fiscal year 2025, reflecting a year-on-year decline of 4.99%, while achieving a reduction in net loss to 19.09 million yuan [2] Group 1: Financial Performance - The company's revenue for 2025 was about 288 million yuan, down 4.99% compared to the previous year [2] - The net profit attributable to the company was a loss of 19.09 million yuan, indicating a reduction in losses year-on-year [2] Group 2: Operational Insights - The reduction in losses was primarily due to impairment provisions made for ongoing projects in 2024 [2] - Despite intense competition in the industry, the company made positive progress in product and marketing efforts [2] - The company implemented more precise and effective cost control measures [2]

Core Viewpoint - The company, Pulaike, has disclosed significant progress in product development and will hold an extraordinary shareholders' meeting to review the election of the board of directors [1] Group 1: Product Development - Multiple avian adenovirus series vaccines have received new veterinary drug registration certificates and are being launched in the market [1] - Nearly 10 products, including a recombinant virus vector trivalent inactivated vaccine for avian influenza and a live vaccine for pseudorabies in pigs, have passed initial review or are in the re-examination stage [1] - Several products are currently in clinical trials or laboratory research stages [1] Group 2: Shareholder Meeting - The company will convene an extraordinary shareholders' meeting on March 6, 2026, to review the election of the sixth board of directors and independent directors [1] Group 3: Stock Performance - As of February 27, 2026, Pulaike's stock price closed at 14.24 yuan, with a daily increase of 0.99% and a cumulative increase of 2.45% over the past five days [1] - The trading volume on February 27 was 84.44 million yuan, with a turnover rate of 1.71% [1] - On February 27, there was a net inflow of approximately 3.08 million yuan in main funds, while on February 26, there was a net outflow of 3.09 million yuan, accounting for 6.98% of the daily trading volume [1] - The stock price fluctuated between a high of 14.37 yuan and a low of 13.79 yuan during this period [1] Group 4: Institutional Insights - The average target price set by institutions is 17.00 yuan, indicating approximately 20% upside potential from the current price [1] - Profit forecasts suggest that the company's net profit is expected to grow by 101.14% year-on-year in 2025, with revenue growth projected at 14.65% year-on-year [1] - Recent institutional ratings have been predominantly neutral, with low frequency of research coverage [1]

Core Viewpoint - The company reported a steady growth in revenue and net profit for the fiscal year 2025, indicating resilience in a competitive market environment [1] Financial Performance - The company achieved an operating revenue of 950 million yuan in 2025, representing an increase of 0.89% compared to the previous year [1] - The net profit attributable to the parent company was 416 million yuan, reflecting an increase of 8.70% year-on-year [1] Industry Context - As of the end of 2025, the national pig inventory reached 42.967 million heads, an increase of 2.24 million heads, or 0.5% year-on-year [1] - The company has been focusing on enhancing its market competitiveness through increased research and development efforts and accelerating the progress of new product development [1]

Core Insights - The poultry vaccine industry is crucial for preventing infectious diseases in poultry and is the foundation of modern poultry farming disease control [1] - China, as a major poultry producer and consumer, has a stable poultry production growth, which provides a solid demand base for the poultry vaccine market [1][8] - The market for poultry vaccines is expected to expand due to increased investment in disease prevention and a shift towards precision immunization models [1][9] Industry Overview - Poultry vaccines are biological agents developed specifically for birds such as chickens, ducks, and turkeys, aimed at inducing specific immune responses to prevent or control infectious diseases [2][3] - The poultry vaccine market can be categorized based on technology, pathogen type, usage characteristics, and vaccination methods [3][4] Market Dynamics - The Chinese poultry vaccine industry has a complete and interconnected supply chain, with high technical barriers in R&D and core raw material supply [5][6] - The demand is driven by government procurement of high-pathogenic avian influenza vaccines and market purchases from large farming groups and small farms [6][8] Policy Environment - The Chinese government has implemented strict management regulations to ensure the quality of veterinary biological products, including several guidelines and policies from 2022 to 2025 [6][7] - The mandatory immunization policy for major diseases has stabilized the vaccine coverage rate at over 98.7%, reinforcing the foundation for disease control in poultry [8] Market Growth Projections - The poultry meat production in China is projected to grow from 23.61 million tons in 2020 to 28.37 million tons by 2025, with a compound annual growth rate of 3.74% [9] - The poultry vaccine market is expected to recover and grow to 69.5 billion yuan in 2024, driven by increasing poultry output and vaccination demand [11][12] Vaccine Segmentation - The poultry vaccine market is primarily composed of inactivated vaccines, live vaccines, and other types, with inactivated vaccines holding over 65% market share [12] - The market for inactivated vaccines is projected to reach 4.65 billion yuan in 2024, while the segment for other vaccines, including genetically engineered and multivalent vaccines, is expected to grow significantly [12] Future Trends - The poultry vaccine industry is anticipated to achieve high-quality development driven by technological innovation, market consolidation, and demand upgrades [13] - Multi-valent vaccines will become the main focus of research and development, with new technologies like mRNA and viral vector vaccines accelerating commercialization [14] - The industry is expected to transition from a single vaccine supply model to a comprehensive service model that includes vaccines, diagnostics, and customized immunization plans [16]

Core Viewpoint - The company acknowledges that its stock price is influenced by multiple factors including macroeconomic conditions, policy changes, and market sentiment [2] Group 1 - The company is committed to high-quality development and will continue to increase its investment in research and development [2] - The company aims to enhance its operational capabilities and provide returns to investors [2]

Core Viewpoint - The article discusses the key deployments in the 2023 Central Document No. 1, focusing on agricultural modernization through technological innovation and the development of new productive forces in agriculture [5][6][7]. Group 1: Key Deployments in Agricultural Technology Innovation - The document emphasizes strengthening integrated innovation by enhancing the overall effectiveness of the agricultural technology innovation system, promoting enterprise-led innovation, and focusing on key areas such as seeds and agricultural machinery [5]. - It highlights the expansion of application scenarios through modern information technology and biotechnology, showcasing the significant role of agricultural drones and artificial intelligence in transforming agricultural practices [6]. - The document stresses the importance of promoting the transformation of agricultural technology achievements to address practical issues faced by farmers, ensuring that innovations reach rural areas effectively [7]. Group 2: Agricultural Bio-Manufacturing Paths Worth Noting - The article identifies high-value utilization of agricultural by-products, such as straw, as a key focus, indicating a shift from mere utilization to profitable applications [8]. - It discusses the potential of synthetic biology to enhance agricultural productivity by producing essential proteins and bio-fertilizers, thereby reducing reliance on chemical fertilizers [10]. - The development of new agricultural applications, including biodegradable materials and bio-pesticides, is highlighted as a means to promote green transformation in agriculture [11]. Group 3: Market Overview of Agricultural Bio-Manufacturing - As of February 9, 2025, there are 161 companies in the A-share market related to the "synthetic biology" concept, with a total market value of approximately 1.69 trillion yuan, averaging 10.5 billion yuan per company [15]. - The agricultural bio-manufacturing sector includes around 20 companies focusing on areas such as animal vaccines and feed additives, indicating a gradual industrial application of synthetic biology in agriculture [17]. - Key companies in this sector are noted for their focus on replacing feed, plant breeding, bio-pesticides, and precision farming, showcasing the diverse applications of synthetic biology in agriculture [17].

Summary of the Conference Call Company Overview - The conference call focused on **普莱柯 (Pulaike)**, a company in the **animal vaccine industry**. The discussion highlighted the company's performance in 2025 and its outlook for 2026. Key Points and Arguments Industry Context - The animal vaccine industry has faced pressure due to fluctuations in the breeding sector and internal competition, leading to a challenging environment for many companies [1][3]. - Despite these challenges, leading companies with strong R&D capabilities have managed to achieve significant growth [1]. Financial Performance - In 2025, 普莱柯 achieved a net profit of approximately **1.176 billion to 1.95 billion** CNY, representing a year-on-year growth of **90% to 110%** [3][4]. - The company reported a nearly **50% increase** in profits during the first three quarters of 2025, driven by the release of poultry vaccine production capacity and rapid growth in the pet business [1][3]. Cost Management and Efficiency - The company has focused on cost reduction and efficiency improvements, resulting in a significant decrease in operating expenses and an increase in net profit margins [1][4][5]. - Sales expense ratios have been continuously declining, indicating effective cost control measures [5][28]. Product Development and Market Strategy - The company plans to continue its focus on high-quality, efficient growth, with expectations to maintain growth in poultry and pet products in 2026 [6][37]. - New product lines, including the **H9 series** and **cash cow series**, are expected to contribute to future growth [11][23]. Market Trends and Pricing - The pricing war in the industry has shown signs of easing, particularly for certain vaccine products, although competition remains intense [10][8]. - The company anticipates that while there may still be pressure on pricing, the overall margin for leading companies remains favorable due to their competitive advantages [10]. Sales Channels and Growth - The company has established a robust distribution network, covering **25 provinces** and over **8,000 pet hospitals** [14][15]. - The pet product segment is experiencing growth rates of over **30%**, with non-medical products seeing even higher growth [15]. Future Outlook - For 2026, the company aims to achieve a net profit target of over **2 billion** CNY, with expectations of returning to historical highs [6][7]. - The poultry vaccine segment is projected to grow by **15% to 20%**, while the pet product segment is expected to exceed **50% growth** [20][37]. Research and Development - The company is actively working on new vaccine projects, including a **African Swine Fever vaccine**, with clinical trials expected to commence soon [31][32]. - The company has made significant investments in R&D to enhance its product offerings and maintain competitive advantages [32]. Challenges and Risks - The company faces ongoing challenges from industry competition and potential impacts from disease outbreaks in livestock, which could affect sales [30][19]. - The overall market environment remains volatile, with external factors influencing the breeding sector's profitability [30]. Additional Important Information - The company has implemented a more refined management approach to sales expenses, linking spending directly to sales outcomes [28]. - There is a strategic focus on expanding international business and product registrations in various countries, aiming for significant growth in export revenues [24]. This summary encapsulates the key insights from the conference call, providing a comprehensive overview of 普莱柯's current status and future prospects in the animal vaccine industry.

Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].